Bomedemstat is an Orally Active and Irreversible LSD1 Inhibitor for SCLC Research
Small cell lung cancer (SCLC) accounts for about 14% of all lung cancer cases. Besides,one of the key regulators of SCLC was identified as lysine-specific demethylase 1A (LSD1 or KDM1A).…